Arpeggio Bio

Summer 2019Active

Arpeggio Bio develops drugs targeting transcription factors using AI…

Save

Arpeggio Bio

Summer 2019Active

Arpeggio Bio develops drugs targeting transcription factors using AI…

Save

Company details

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

Location

Boulder, CO, USA

Founded

Unknown

Upgrade to Pro, then request the Arpeggio Bio teardown.

This company does not have a completed analysis yet. Choose a Pro plan first, then use one of your 5 monthly research requests to have our agent investigate Arpeggio Bio. The full teardown, rebuild plan, and technical specs unlock when it lands.

Use Pro to request the first Arpeggio Bio teardown and keep the finished report in your account.
Read every completed teardown and rebuild plan already in the database.
Unlock implementation-ready technical specs and 5 fresh research requests each month.

Choose your Pro plan

$20/ month

Find one worth rebuilding, get the teardown, open the implementation-ready specs, and use fresh report requests when you want deeper research.

See Pro plans

Full teardown library

Specs for every company

5 fresh requests / month

CLI for agent imports